Overall, MPN patients, particularly primary myelofibrosis (PMF) patients, and patients with MDS, MDS/MPN or (secondary) AML who carry EZH2 mutations have a worse prognosis compared to patients with wild-type EZH2 [20,22,23,24]. The gene discussed is EZH2; the disease is primary myelofibrosis.